News in brief: Safe switching to biosimilars; Antibiotic resistance in C. diff; Stronger mesalazine on PBS

Reassurance on multiple IFX switching  Multiple switches from originator infliximab to its biosimilars does not appear to impact efficacy, immunogenicity or safety of anti-TNF therapy in patients with IBD. A French study of 158 patients compared outcomes after a single switch to a biosimilar with outcomes after a double switch to a second biosimilar. It ...

Already a member?

Login to keep reading.

© 2021 the limbic